Qiagen, Abbott Enter into Molecular Dx Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen and Abbott late on Tuesday announced a broad molecular diagnostics agreement covering HIV, human papillomavirus, and hepatitis C.

Under the terms of the deal, Qiagen will receive kits from Abbott for a PCR-based molecular assay for HIV-1 viral load testing in the US and Canada. In return, it will provide Abbott certain key products needed for a PCR-based HPV test in the US and Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.